GB CC Sirius 2015

1

New In Vitro Methods for Bio-Relevant Analysis of Both Small Molecules and Proteins

George ButcherTechnical Product Manager, Sirius Analytical

Forest Row, [email protected]

An introduction to Sirius Sirius was founded in 1989. We are a manufacturer and vendor of

instrumentation for measurement of physicochemical parameters. We also provide an Analytical Service, and measure thousands of

samples for hundreds of customers, worldwide, each year. In the US, we are based in Beverly, MA.

www.sirius-analytical.com

My presentation today:

- The need for improved in-vitro testing models

- Sirius inForm – dynamic dissolution testing instrument

- Introducing Sirius Scissor – a new instrument for biotherapeutics

- Example studies from both systems

4

GI Conditions & traditional dissolution

5

Historically:

• Develop pharmaceutical products to be manufactured in bulk

• Test criteria based on reproducibility of manufacture

The Rise of Formulation

Currently:

• Enabling techniques to improve bioavailability of BCS class 2 and 4 API’s.

• More recently formulation has become more focussed towards pharmacokinetics

• Requires a deeper understanding of the physicochemical properties of API’s in the presence

of the formulation ingredients for achieving required exposure levels

• Understanding the solubility and dissolution behaviour of API’s is an important part of

formulation design

6

Traditional dissolution testing is a quality performance test (drug release and QC)

Traditional Dissolution is not biorelevant…

Slide adapted from Gregory Amidon: “Oral Bioperformance and 21st century dissolution testing”?

7

New tools required for drug development

8

European IMI-OrBiTo* Program

* OrBiTo = Oral Biopharmaceutics Tools

http://www.orbitoproject.eu/

Platform for automated biorelevant dissolution and solubility testing with support for final dosage forms

http://www.sirius-analytical.com/products/inform

10

Sirius inForm - new instrument for use in Formulation studies

11

Automated dispensing of acid, base, solvents, buffers and SIFs during an assay

Stirrer, pH and UV probes. Sample vial in Peltier block. Automated sample addition.

Dispensers for Automated addition of media, titrants, solvents

12



Robotic arms for vial handling and assay probe handling

13



20 Vial autoloader, HPLC vial tray, sonicator, automated cleaning, vacuum manifold, tablet holder

The inForm measurement cell

15

pH electrode

UV probe

Temperature probe

Reagent capillaries

Stirrer

Inert gas

16

Sample tablet holder can be lowered from

above.

Basket for powders and

dosage forms.

Three ways to measure concentration

• pH-metric– Good for solutions whose pH is < 3 units from pKa

• In-situ UV– Good for drugs that absorb UV

• Automated Off-line sampling– Best method if samples are very turbid

17

18

Dru

g co

ncen

trati

on

Time

“Spring”

Equilibrium solubility

Diagram adapted fromBrouwers, J. et al. J. Pharm. Sci. 2009, 98 (8), 2549-2572.

Crystalline sample

“Spring” with “Parachute”

TRADITIONAL DISSOLUTION

“Spring and Parachute” model

19

Supersaturated, sample is precipitating

Subsaturated, sample is dissolving

Supersaturated, sample is fully dissolved

Precipitate appears


Time

0

2

4

6

8

10

0 30 60 90 120

Conc

entr

ation

(μM

)

Time (minutes)

20

Dissolution of Warfarin* powder at pH 3.1

* Warfarin is an acid, pKa 4.94


21

0 30 60 90 120Time (minutes)

0

100

200

300

400C

once

ntra

tion

(µM

)

Same graph, different scaling


0

100

200

300

400C

once

ntra

tion

of n

eutr

al s

pec

ies

(µM

)

22

Warfarin aqueous CheqSol: a “Spring”


Precipitate appears

Kinetic solubility

0 30 60 90 120Time (minutes)

0

100

200

300

400C

once

ntra

tion

of n

eutr

al s

pec

ies

(µM

)

23

0 30 60 90 120Time (minutes)

Warfarin and PVP*: a “Parachute”

* Polyvinylpyrrolidone. With thanks to Ashland Specialty Chemicals

24

How we measure concentrations by in-situ UV

In-situ UV

25

pH Versus Time

20:00 30:00Time(minutes:seconds)

3

5

7pH

N

O

O

CH3

OH

Cl

OCH3

IndomethacinAcid, pKa 4.1

IndomethacinTitration in linear buffer solutionMeasure spectra at each pH point

2 4 6 8pH (Concentration scale)

0.0

0.5

1.0

1.5

2.0

Abs

orba

nce

0

50

100

150

200

Species C

oncentration (µM)

5.11

250 300 350 400Wavelength (nm)

0.0

0.5

1.0

1.5

2.0A

bsor

banc

e

0

5000

10000

15000

20000

25000 Molar absorption (/cm

/M)

26

Molar Absorption Coefficients (MECs)

N

O

O

CH3

OH

Cl

OCH3

Comparing MEC with dissolution data

27

250 300 350 400Wavelength (nm)

0.0

0.5

1.0

1.5

Abs

orba

nce

N

O

O

CH3

OH

Cl

OCH3

28

inForm case studies

Client Evaluation 1 – A major US pharma company

29

• API is a weak acid with pKa = 9 and log P = 3

• Four forms supplied

– Crystalline API, powder

– Formulated crystalline API, extracted from a capsule

– Amorphous solid dispersion, powder

– Formulated amorphous solid dispersion, part of tablet

• Equal weight of API used in each experiment

• All experiments at 37°C

30

Dilution, FaSSIF introduced

Gastric period: Acetate-phosphate

buffer + HCl

Gastric emptying. pH raised with NaOH

Biorelevant dissolution. FaSSIF added

Intestinal period

31

Biorelevant dissolution

1

2

3

4

5

6

7

0

5

10

15

0 2 4 6

pH

Mas

s of d

isso

lved

API

(mg)

Time (hours)

Formulated crystal API

Crystal API

Solid dispersion

Formulated solid dispersion

pH

Crystalline samples

1

2

3

4

5

6

7

0

200

400

600

800

0 1 2

pH

Mas

s of d

isso

lved

API

(μg)

Time (hours)

Formulated crystal API

Crystal API

pH

Crystalline

Amorphous

Biphasic dissolution. Nonanol added

32

Gastric period: Acetate-phosphate

buffer + HCl

Dilution, lipid layer introduced

Gastric emptying. pH raised with NaOH

Drug dissolving in aqueous solution

Drug partitioned into lipid

Total amount dissolved

Intestinal period

1

2

3

4

5

6

7

0

5

10

15

0 1 2

pH

Mas

s of d

isso

lved

API

(mg)

Time (hours)

Crystal API, lipidFormulated crystal API, lipidFormulated crystal API, aq.Crystal API, aqueouspH

1

2

3

4

5

6

7

0

5

10

15

0 1 2

pH

Mas

s dis

solv

ed o

f API

(mg)

Time (hours)

Formulated solid dispersion, lipid

Solid disperion, lipid

Formulated solid dispersion, aq.

Solid dispersion, aqueous

pH

Biphasic dissolution

33

Crystalline API- may be overstimated

Formulated solid dispersion - may be overestimated

Crystalline

Amorphous

Client Evaluation 2 – Small US Pharma

• Controlled supersaturation• Solvent quench method: concentrations by UV• Two examples

– Bifonazole, Droperidol• FaSSIF and various additives used to test the

effect on supersaturation/precipitation rate

34

36

Tyndall-Rayleigh scattering correction

BEFORE

AFTER

OK for data analysis

37

Aqueous

Pluronics

PVP

Soluplus

FaSSIFHPMC

DroperidolBase, pKa 8.2Controlled supersaturation at pH 6.8

BifonazoleBase, pKa 6.6Controlled supersaturation at pH 5

http://en.wikipedia.org/wiki/File:Bifonazole.svg

http://en.wikipedia.org/wiki/File:Droperidol.svg

38

Summary of inForm PlatformThe Sirius inForm instrument is a useful tool for early development and

formulation scientists providing more predictive tools for drug performance

• Sirius inForm can set up a wide range of experimental conditions

• Automated biorelevant solubility & dissolution

• Automated biphasic dissolution

• Measuring supersaturation & precipitation behavior

• Dealing with turbidity

• Innovative tests for investigating IVIVC

39

What about Protein formulations?

Introducing Sirius “Scissor”: Sub Cutaneous Injection Site SimulatOR

A New In Vitro Test for Injection Site Events for Biopharmaceuticals

Importance of Subcutaneous Injections

1989 to 2012 Biotechnology products (mostly proteins and peptides)

grew in number from 13 to 210 Sales increased to US$163 billion.

2001 to 2012 Biotech products accounted for 71% revenues for the

ten top-selling pharmaceuticals in 2012, up from 7% in 2001.

Move to subcutaneous (SC) injections Currently, ~ 40 protein and peptide drugs are given SC Therapies shifting care to home treatment will increase

this number of SC drugs

41

Potential Issues for SC and IO injections

Current formulations are designed to• Keep API stable in a vial for several years• Minimize injection volume (high concentration)• Minimize pain upon injection

APIs are stressed upon injection by• Transition from formulation to homeostatic conditions immediately

after injection- Physical stress due to change in pH- Transition through isoelectric point?- Change in concentration of stabilizing agents- Altered interactions with stabilizing agents

42

Possible Events After Injection

There are currently no in vitro methods available to examine potential events that might be experienced by an API during its transition from an injected formulation to the steady-state conditions of the injection site environment.

43

What We Know and What is Needed

What we know• Site to site and patient to patient variability is seen for bioavailability (%BA) of

many biopharmaceuticals.• No animal model correlates to (%BA) observed in man.• Conditions/characteristics of physical and chemical environments of the

injection site are species specific.• Insolubility/precipitation upon injection can lead to cellular responses and

macrophage clearance.

What we need• A versatile in vitro model to examine the potential impact of specific, individual

post-injection events.• A dynamic system that emulates approximate time and conditions for post-

injection transitions.

44

Design of the Scissor instrument

45

Schematic of the Scissor system chamber featuring: injection cartridge acting as a simulated injection site; pH probe for monitoring the pH within the cartridge; light source and detector for monitoring aggregation events; chamber of physiological buffer; thermocouple and heater/stirrer

Sirius Scissor - Schematic

46

In vitro study of subcutaneous injection of two insulin formulations

Two insulin formulations; Insuman Rapid (fast acting) and Insuman Basal (slow acting)

Light %T of Insuman Rapid and Basal

PK of Insuman Rapid and Basal

Fraction appearing in ISF buffer (data by HPLC)

47

Pharma Study - Outcome Potentially Important for mAbs@

6hr

s

48

Our Approach

• No pre-clinical model has been identified that will correlate with human in vivo outcomes

• This model is not intended to examine cell-mediated or immune responses

• Our in vitro model simulates dynamic events at the site of injection site of a drug

• The model monitors ECM interactions, pH changes, protein turbidity, excipients fate and spectroscopic properties.

• The system models events for several hours at physiological conditions

• Future studies will focus on correlations pre-clinical human in vivo outcomes to establish a predictive tool.

49

Scissor - Acknowledgements

GenentechVikas SharmaStefan FicsherSreedhara AlavattamTom PatapoffAnn Daugherty

Sirius AnalyticalJohn ComerKarl BoxGeorge ButcherBrett Hughes

University of BathRandy MrsnyHanne KinnunenJenni SobleAlison EvansMatt Young

50

•Thanks for listening!

•Any questions?

[email protected]

www.sirius-analytical.com

Make formulation decisions earlier with detailed bio-relevant data

GB CC Sirius 2015

Documents

Transcript of GB CC Sirius 2015